secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001213900-24-057240
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics closes $8.75M public offering to repay debt and fund FDA work
--------------------------------------------------------------------------------

- Gross proceeds $8.75M from sale of 5,368,098 units at $1.63/unit.
- Units consist of 1 share (or pre-funded warrant), 2 Class C warrants, 1 Class D warrant.
- Net proceeds to repay $2.3M debt and fund FDA approval (incl. clinical studies), R&D, working capital.
- Class C warrants ($1.96 strike, 5-year term) require stockholder approval to become exercisable.
- Underwriting discount 8.5%; Aegis Capital Corp. acted as sole underwriter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390024057240/0001213900-24-057240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390024057240/ea0208666-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-057240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer